Potential role for mitogen-activated protein kinase phosphatase-1 in the development of atherosclerotic lesions in mouse models

Arteriosclerosis, Thrombosis, and Vascular Biology
Srinivasa T ReddyAlan M Fogelman

Abstract

Mitogen-activated protein kinase phosphatase-1 (MKP-1) is one of several oxidized-l-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (Ox-PAPC)-induced genes identified in human aortic endothelial cells (HAEC). We previously reported that MKP-1 activity is required for Ox-PAPC-mediated endothelial/monocyte interactions; however, an in vivo role of MKP-1 in atherogenesis has not been investigated. We now report that MKP-1 protein is expressed in the atherosclerotic lesions of mice. MKP-1 mRNA expression is highly induced in C57BL6/J mice on an atherogenic diet, low-density lipoprotein receptor (LDLR) (-/-) mice on a Western diet, and 10-week or older ApoE (-/-) mice on a chow diet. In ApoE (-/-) mice treated with 1 mg/mL of sodium orthovanadate (NaOV), a specific inhibitor of tyrosine phosphatases including MKP-1, total phosphatase activity and MKP-1 protein were decreased in both the aortic lesions and liver lysates. In 3 animal models of atherosclerosis [C57BL6/J mice on an atherogenic diet for 15 weeks, LDLR (-/-) mice on a Western diet for 10 weeks, and ApoE (-/-) mice on a chow diet for 8 weeks], mice treated with NaOV had significantly smaller atherosclerotic lesions when compared with the control group. MKP-...Continue Reading

References

Mar 28, 1991·Nature·K L GuanJ E Dixon
Jan 1, 1991·Methods in Enzymology·J A Gordon
Jan 1, 1996·European Urology·C Magi-Galluzzi, M Loda
Feb 17, 2001·European Journal of Immunology·M J Grimshaw, F R Balkwill
Aug 2, 2002·Current Opinion in Lipidology·Mohamad NavabSrinu T Ready
Nov 27, 2002·Vascular Pharmacology·Srinivasa T ReddyAlan M Fogelman

❮ Previous
Next ❯

Citations

Aug 19, 2009·Antioxidants & Redox Signaling·Valery N BochkovJohannes Stöckl
Dec 19, 2008·American Journal of Physiology. Cell Physiology·Angela M WhetzelCatherine C Hedrick
Nov 3, 2010·Proceedings of the National Academy of Sciences of the United States of America·Feng SuRobin Farias-Eisner
Feb 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Willmar D PatinoPaul M Hwang
Jul 13, 2007·Molecular and Cellular Endocrinology·Alexandros Vegiopoulos, Stephan Herzig
Nov 14, 2015·Journal of Cellular Physiology·Bradley S FergusonRon F Morrison
Mar 7, 2009·Circulation Research·Alan R CollinsWilla A Hsueh
Mar 26, 2005·The Journal of Biological Chemistry·Meghan E McMullenKevin M Pumiglia
Jun 23, 2005·The Journal of Biological Chemistry·Louis RagoliaYoshihiro Urade
Nov 10, 2010·Expert Opinion on Therapeutic Targets·Rachel J Roth Flach, Anton M Bennett
Jun 15, 2012·Cellular and Molecular Life Sciences : CMLS·Ahmed LawanAnton M Bennett
May 30, 2017·Cardiovascular Drugs and Therapy·Ingrid WebsterBarbara Huisamen
Nov 6, 2014·American Journal of Physiology. Endocrinology and Metabolism·Abdelkrim KhadirMohammed Dehbi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.